

Thiru Balasubramaniam
Managing Director
KEI Europe
CP 2100
1 Route des Morillons
1211 Genève 2
Suisse

26 August 2014

via e-mail: thiru@keieurope.org

Dear Mr. Balasubramaniam

Request for licences for territory of Romania

We refer to your letters of 8th and 29th July 2014. Thank you for your interest in our products and for enquiring into the licensing of our patents for Romania.

As you know, our company takes great pride in its continuous efforts to research and develop innovative medicines for treating people with life-threatening illnesses worldwide. We are therefore especially proud that we can now offer Sovaldi®, an important therapeutic advance in the treatment of hepatitis C virus infections. We very much hope Sovaldi® will increase the number of patients who can be treated and ultimately cured of this life-threatening disease.

The European Commission's approval for the marketing of Sovaldi® in EU member states on 16 January 2014 has opened up the possibility that EU patients will be able to benefit from this innovative treatment.

As you may know, our company has already publicly indicated that it is committed to working with local governments and health authorities in the EU so that Sovaldi® becomes available to patients as quickly as possible.

Please be assured that we plan to engage with the Romanian government and other relevant Romanian authorities to ensure that Romanian patients infected with hepatitis C virus have access to Sovaldi® as soon as possible.

In relation to the licensing of patents covering Sovaldi® and other patents covering Gilead HCV treatments, our company has always indicated that it is open to collaborations of all kinds, whether these are in science, academia, business or with local communities. Moreover, we believe that such partnerships enhance our ability to develop innovative medicines and to deliver them to patients as efficiently as possible.

Our company is therefore committed to forming and strengthening partnerships where the possibility for such partnerships arises and the context allows. Unfortunately, it is too early for Gilead to properly assess possible partnerships for the marketing of Sovaldi® / ledipasvir / GS-5816 in Romania at present.

However, we remain, as always, open to consider possible partnerships that can improve our ability to develop innovative medicines and to deliver them to patients.

Sincerely



Rudi Ertl
Senior Vice-President, EMEA
Gilead Sciences Europe Ltd